- Home
- HTD vs XERS Comparison
HTD vs XERS Comparison
Compare HTD & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTD
- XERS
- Stock Information
- Founded
- HTD 2004
- XERS 2005
- Country
- HTD United States
- XERS United States
- Employees
- HTD N/A
- XERS N/A
- Industry
- HTD Finance Companies
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- HTD Finance
- XERS Health Care
- Exchange
- HTD Nasdaq
- XERS Nasdaq
- Market Cap
- HTD 850.4M
- XERS 752.7M
- IPO Year
- HTD N/A
- XERS 2018
- Fundamental
- Price
- HTD $24.51
- XERS $7.30
- Analyst Decision
- HTD
- XERS Strong Buy
- Analyst Count
- HTD 0
- XERS 7
- Target Price
- HTD N/A
- XERS $6.79
- AVG Volume (30 Days)
- HTD 92.3K
- XERS 3.0M
- Earning Date
- HTD 01-01-0001
- XERS 08-07-2025
- Dividend Yield
- HTD 8.59%
- XERS N/A
- EPS Growth
- HTD N/A
- XERS N/A
- EPS
- HTD N/A
- XERS N/A
- Revenue
- HTD N/A
- XERS $246,025,000.00
- Revenue This Year
- HTD N/A
- XERS $35.31
- Revenue Next Year
- HTD N/A
- XERS $19.65
- P/E Ratio
- HTD N/A
- XERS N/A
- Revenue Growth
- HTD N/A
- XERS 35.62
- 52 Week Low
- HTD $16.17
- XERS $2.39
- 52 Week High
- HTD $22.13
- XERS $7.61
- Technical
- Relative Strength Index (RSI)
- HTD 61.54
- XERS 84.68
- Support Level
- HTD $24.24
- XERS $5.25
- Resistance Level
- HTD $24.70
- XERS $7.61
- Average True Range (ATR)
- HTD 0.23
- XERS 0.38
- MACD
- HTD -0.02
- XERS 0.21
- Stochastic Oscillator
- HTD 71.41
- XERS 88.69
About HTD John Hancock Tax Advantaged Dividend Income Fund of Beneficial Interest
John Hancock Tax-advantaged Div Inc Fd is a closed-end, diversified management investment company. Its investment objective is to provide a high after-tax total return from dividend income and capital appreciation. The fund's portfolio composition consists of common stocks, preferred securities, corporate bonds, convertible bonds, and short-term investments. Its sector composition comprises utilities, financials, energy, telecommunication services, industrials, healthcare, real estate, consumer discretionary and short-term investments.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).